Actively Recruiting
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
Led by Zhejiang Cancer Hospital · Updated on 2025-02-18
44
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to observe and explore the efficacy and safety of Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) regimen as first-line therapy for primary central nervous system diffuse large B-cell lymphomas(PCNS DLBCL)
CONDITIONS
Official Title
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients voluntarily join the study, sign informed consent, and can comply with study requirements
- Age between 18 and 75 years at the time of consent
- Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score between 0 and 3
- Histopathologically confirmed newly diagnosed primary central nervous system diffuse large B-cell lymphoma
- Presence of intracranial evaluable lesions with long diameter >1.5cm and short diameter >1cm
- No prior systemic therapy except hormone use for complications
- Expected survival longer than 3 months
- Female patients of reproductive age agree to use birth control during study and for 6 months after
- Negative serum pregnancy test within 7 days before enrollment and non-lactating
- Male patients agree to use contraception during study and for 6 months after completion
You will not qualify if you...
- Prior antitumor or targeted therapy
- Major surgery within the past 3 weeks
- Severe or uncontrolled comorbid conditions including symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, active peptic ulcer disease, severe hemorrhagic disorders, or history of spontaneous bleeding requiring medical intervention
- Active infection requiring systemic antimicrobial therapy within 14 days before study treatment
- Pregnant or breastfeeding
- Participation in other clinical studies or start of study drugs less than 4 weeks after finishing previous clinical study treatment
- Concomitant diseases that may endanger safety or interfere with study completion as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
Research Team
H
Haiyan Yang, PhD
CONTACT
H
Haifeng Yu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here